Ezogabine (retigabine)

K K Jain MD (Dr. Jain is a consultant in neurology and has no relevant financial relationships to disclose.)
Originally released December 30, 2005; last updated September 19, 2016; expires September 19, 2019

Historical note and terminology

Ezogabine, a K channel opener used for treatment of partial-onset seizures in adults, was developed by Valeant Pharmaceuticals and GlaxoSmithKline. In 2011, it was approved by the European Medicines Agency under the trade name Trobalt and by the FDA, under the trade name Potiga. The drug is known as "ezogabine" in the United States and "retigabine" elsewhere.

The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.

If you are a subscriber, please log in.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.

If you have never registered before, click Learn More about MedLink Neurology  or view available Service Plans.